vs
Lineage Cell Therapeutics, Inc.（LCTX）与Rithm Property Trust Inc.（RPT）财务数据对比。点击上方公司名可切换其他公司
Lineage Cell Therapeutics, Inc.的季度营收约是Rithm Property Trust Inc.的1.9倍（$6.6M vs $3.4M），Rithm Property Trust Inc.净利率更高（95.4% vs 12.9%，领先82.5%），Lineage Cell Therapeutics, Inc.同比增速更快（130.4% vs -39.7%），过去两年Lineage Cell Therapeutics, Inc.的营收复合增速更高（113.9% vs -43.2%）
谱系细胞治疗公司是一家处于临床阶段的生物科技企业，专注于开发满足未竟医疗需求的新型细胞疗法。其研发项目依托自主成熟的细胞疗法专有平台，以及内部配套的研发与生产能力，可利用多能细胞和祖细胞原料，开发制造专业化的终末分化人类细胞，推进对应疗法落地。
Rithm Property Trust Inc.旗下的里思资本是一家总部位于纽约的美国投资管理公司，核心业务聚焦于房地产投资及另类投资领域，是该赛道颇具影响力的专业投资机构。
LCTX vs RPT — 直观对比
营收规模更大
LCTX
是对方的1.9倍
$3.4M
营收增速更快
LCTX
高出170.1%
-39.7%
净利率更高
RPT
高出82.5%
12.9%
两年增速更快
LCTX
近两年复合增速
-43.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $6.6M | $3.4M |
| 净利润 | $851.0K | $3.2M |
| 毛利率 | — | — |
| 营业利润率 | -99.1% | 99.6% |
| 净利率 | 12.9% | 95.4% |
| 营收同比 | 130.4% | -39.7% |
| 净利润同比 | 126.0% | 11.2% |
| 每股收益（稀释后） | $0.00 | $-0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LCTXRPT
| Q4 25 | $6.6M | $3.4M | ||
| Q3 25 | $3.7M | $4.0M | ||
| Q2 25 | $2.8M | $4.2M | ||
| Q1 25 | $1.5M | $249.0K | ||
| Q4 24 | $2.9M | — | ||
| Q3 24 | $3.8M | — | ||
| Q2 24 | $1.4M | — | ||
| Q1 24 | $1.4M | — |
净利润LCTXRPT
| Q4 25 | $851.0K | $3.2M | ||
| Q3 25 | $-29.8M | $-273.0K | ||
| Q2 25 | $-30.5M | $1.9M | ||
| Q1 25 | $-4.1M | $-3.4M | ||
| Q4 24 | $-3.3M | — | ||
| Q3 24 | $-3.0M | — | ||
| Q2 24 | $-5.8M | — | ||
| Q1 24 | $-6.5M | — |
毛利率LCTXRPT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 97.6% | — | ||
| Q4 24 | 94.6% | — | ||
| Q3 24 | 99.0% | — | ||
| Q2 24 | 96.9% | — | ||
| Q1 24 | 93.2% | — |
营业利润率LCTXRPT
| Q4 25 | -99.1% | 99.6% | ||
| Q3 25 | -102.9% | -6.2% | ||
| Q2 25 | -715.4% | 45.7% | ||
| Q1 25 | -433.1% | -1416.5% | ||
| Q4 24 | -178.2% | — | ||
| Q3 24 | -101.6% | — | ||
| Q2 24 | -416.7% | — | ||
| Q1 24 | -461.3% | — |
净利率LCTXRPT
| Q4 25 | 12.9% | 95.4% | ||
| Q3 25 | -809.0% | -6.8% | ||
| Q2 25 | -1101.8% | 45.1% | ||
| Q1 25 | -275.6% | -1363.1% | ||
| Q4 24 | -114.1% | — | ||
| Q3 24 | -80.3% | — | ||
| Q2 24 | -409.1% | — | ||
| Q1 24 | -453.0% | — |
每股收益（稀释后）LCTXRPT
| Q4 25 | $0.00 | $-0.26 | ||
| Q3 25 | $-0.13 | $-0.03 | ||
| Q2 25 | $-0.13 | $0.01 | ||
| Q1 25 | $-0.02 | $-0.08 | ||
| Q4 24 | $0.00 | — | ||
| Q3 24 | $-0.02 | — | ||
| Q2 24 | $-0.03 | — | ||
| Q1 24 | $-0.04 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $55.8M | $79.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $44.5M | $291.6M |
| 总资产 | $112.6M | $1.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LCTXRPT
| Q4 25 | $55.8M | $79.3M | ||
| Q3 25 | $40.5M | $81.4M | ||
| Q2 25 | $42.3M | $98.6M | ||
| Q1 25 | $47.9M | $97.4M | ||
| Q4 24 | $47.8M | — | ||
| Q3 24 | $32.7M | — | ||
| Q2 24 | $38.5M | — | ||
| Q1 24 | $43.6M | — |
股东权益LCTXRPT
| Q4 25 | $44.5M | $291.6M | ||
| Q3 25 | $22.0M | $291.7M | ||
| Q2 25 | $48.4M | $294.7M | ||
| Q1 25 | $79.0M | $296.1M | ||
| Q4 24 | $78.4M | — | ||
| Q3 24 | $66.2M | — | ||
| Q2 24 | $68.3M | — | ||
| Q1 24 | $72.4M | — |
总资产LCTXRPT
| Q4 25 | $112.6M | $1.0B | ||
| Q3 25 | $89.6M | $1.0B | ||
| Q2 25 | $90.8M | $1.0B | ||
| Q1 25 | $111.8M | $1.0B | ||
| Q4 24 | $113.2M | — | ||
| Q3 24 | $96.6M | — | ||
| Q2 24 | $102.8M | — | ||
| Q1 24 | $108.5M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-4.9M | $-8.3M |
| 自由现金流经营现金流 - 资本支出 | $-5.3M | — |
| 自由现金流率自由现金流/营收 | -79.9% | — |
| 资本支出强度资本支出/营收 | 6.0% | — |
| 现金转化率经营现金流/净利润 | -5.73× | -2.56× |
| 过去12个月自由现金流最近4个季度 | $-19.4M | — |
8季度趋势，按日历期对齐
经营现金流LCTXRPT
| Q4 25 | $-4.9M | $-8.3M | ||
| Q3 25 | $-3.6M | $-5.8M | ||
| Q2 25 | $-5.5M | $-25.0K | ||
| Q1 25 | $-4.9M | $-1.6M | ||
| Q4 24 | $-6.3M | — | ||
| Q3 24 | $-5.8M | — | ||
| Q2 24 | $-5.2M | — | ||
| Q1 24 | $-5.8M | — |
自由现金流LCTXRPT
| Q4 25 | $-5.3M | — | ||
| Q3 25 | $-3.6M | — | ||
| Q2 25 | $-5.6M | — | ||
| Q1 25 | $-5.0M | — | ||
| Q4 24 | $-6.7M | — | ||
| Q3 24 | $-5.9M | — | ||
| Q2 24 | $-5.2M | — | ||
| Q1 24 | $-5.8M | — |
自由现金流率LCTXRPT
| Q4 25 | -79.9% | — | ||
| Q3 25 | -98.6% | — | ||
| Q2 25 | -200.8% | — | ||
| Q1 25 | -331.8% | — | ||
| Q4 24 | -234.0% | — | ||
| Q3 24 | -156.1% | — | ||
| Q2 24 | -371.2% | — | ||
| Q1 24 | -403.1% | — |
资本支出强度LCTXRPT
| Q4 25 | 6.0% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | 6.5% | — | ||
| Q4 24 | 12.7% | — | ||
| Q3 24 | 3.0% | — | ||
| Q2 24 | 3.6% | — | ||
| Q1 24 | 2.6% | — |
现金转化率LCTXRPT
| Q4 25 | -5.73× | -2.56× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.01× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LCTX
| Collaboration Revenues | $6.3M | 95% |
| Other | $345.0K | 5% |
RPT
暂无分部数据
